Immuron Limited (NASDAQ: IMRN) is spiking, up roughly 52% to $1.69 from Thursday’s $1.11 close, after announcing an exclusive U.S. distribution deal with Calmino Group…
September 04, 2026
September 04, 2026
AbbVie’s Etentamig Shows Strong Results in Phase 3 Blood Cancer Study
Key Points AbbVie’s experimental drug etentamig helped more patients with hard-to-treat multiple myeloma respond to treatment than standard therapies. The drug cut the risk of…
September 04, 2026
Immuron Expands U.S. Digestive Health Portfolio With PROIBS Launch
Key Points Immuron Limited signed an exclusive U.S. distribution agreement with Calmino Group AB for PROIBS®. PROIBS is a European-certified medical device designed to address…
September 03, 2026
Kala Bio Secures Exclusive U.S. Rights to Virotek’s Ophthalmology Genetic Testing Program
Key Points Kala Bio finalized an exclusive U.S. distribution and reseller agreement with Virotek for its ophthalmology genetic testing and screening program. The agreement begins…
Key Points Compass Pathways was named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech, and Fierce Healthcare. The recognition highlights organizations and…
September 01, 2026
Ocugen Launches Pivotal Gene Therapy Trial for Vision-Threatening Geographic Atrophy
Key Points Ocugen has dosed the first patient in ArMaDa3, its global Phase 3 registrational trial of OCU410 for geographic atrophy caused by dry age-related…
September 01, 2026
MIRA-55 Moves Closer to IND as MIRA Completes Key Toxicology Studies
Key Points MIRA Pharmaceuticals completed seven-day dose-range finding toxicology and toxicokinetic studies of its oral, non-opioid inflammatory-pain candidate, MIRA-55, in rats and dogs. The studies…
September 01, 2026
bioAffinity Expands CyPath Lung Toward Monitoring Lung Cancer Survivors
Key Points bioAffinity Technologies is advancing CyPath® Lung for use in monitoring lung cancer survivors after treatment. The noninvasive sputum-based test is designed to provide…
Key Points ACADIA reported Q2 2026 revenue of approximately $308 million and net income of $31.5 million. Management increased 2026 revenue guidance to $1.24 billion–$1.30…
August 31, 2026
Numinus Wellness Reports 29% Quarterly Revenue Growth as Practitioner Training Accelerates
Key Points Q4 fiscal 2025 revenue increased 29% sequentially to C$2.33 million. Gross profit rose 63.5% from the prior quarter to C$1.42 million. Gross margin…
August 28, 2026
Quoin Reports Statistically Significant Interim Netherton Data, Announces Up to $50 Million Financing
Four of six patients met the primary endpoint at Week 12, while results showed improvement across multiple clinical measures. A concurrent institutional financing could extend…
Key Points BioXcel filed Chapter 11 cases in Delaware to conduct a court-supervised sale of substantially all company assets. Teva Pharmaceuticals International GmbH signed an…